Cargando…

Thwarting Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) with Common Bean: Dose- and Sex-Dependent Protection against Hepatic Steatosis

Hepatic steatosis signifies onset of metabolic dysfunction-associated fatty liver disease (MAFLD) caused by disrupted metabolic homeostasis compromising liver function. Regular consumption of common beans reduces the risk of metabolic impairment, but its effective dose, the impact of biological sex,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lutsiv, Tymofiy, McGinley, John N., Neil, Elizabeth S., Foster, Michelle T., Thompson, Henry J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9920904/ https://www.ncbi.nlm.nih.gov/pubmed/36771233 http://dx.doi.org/10.3390/nu15030526

Ejemplares similares

Consumption of Common Bean Suppresses the Obesogenic Increase in Adipose Depot Mass: Impact of Dose and Biological Sex
por: Thompson, Henry J., et al.
Publicado: (2023)

Relandscaping the Gut Microbiota with a Whole Food: Dose–Response Effects to Common Bean
por: Lutsiv, Tymofiy, et al.
Publicado: (2022)

Cell Signaling Pathways in Mammary Carcinoma Induced in Rats with Low versus High Inherent Aerobic Capacity
por: Lutsiv, Tymofiy, et al.
Publicado: (2019)

Compositional Changes of the High-Fat Diet-Induced Gut Microbiota upon Consumption of Common Pulses
por: Lutsiv, Tymofiy, et al.
Publicado: (2021)

Dietary Oncopharmacognosy as a Crosswalk between Precision Oncology and Precision Nutrition
por: Thompson, Henry J., et al.
Publicado: (2023)

Beneficial Effects of Common Bean on Adiposity and Lipid Metabolism
por: Thompson, Henry J., et al.
Publicado: (2017)

Natural Products in Precision Oncology: Plant-Based Small Molecule Inhibitors of Protein Kinases for Cancer Chemoprevention
por: Thompson, Henry J., et al.
Publicado: (2023)

Validation of nonalcoholic fatty liver disease (NAFLD) related steatosis indices in metabolic associated fatty liver disease (MAFLD) and comparison of the diagnostic accuracy between NAFLD and MAFLD
por: Chen, Jie, et al.
Publicado: (2023)

A43 SEX DIFFERENCES IN THE ASSOCIATION OF HIV WITH METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASE (MAFLD)
por: Kablawi, D, et al.
Publicado: (2023)

Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) and Viral Hepatitis
por: Wang, Xiaolin, et al.
Publicado: (2022)

Fibrogenic Pathways in Metabolic Dysfunction Associated Fatty Liver Disease (MAFLD)
por: Subramanian, Pallavi, et al.
Publicado: (2022)

Thwarting the Divine Will
Publicado: (1891)

Vitamin D and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): An Update
por: Barchetta, Ilaria, et al.
Publicado: (2020)

White Kidney Bean (Phaseolus Vulgaris L.) Consumption Reduces Fat Accumulation in a Polygenic Mouse Model of Obesity
por: Neil, Elizabeth S., et al.
Publicado: (2019)

Pharmacological Therapeutics: Current Trends for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
por: Prasoppokakorn, Thaninee, et al.
Publicado: (2021)

MAFLD/NAFLD Biopsy-Free Scoring Systems for Hepatic Steatosis, NASH, and Fibrosis Diagnosis
por: Segura-Azuara, Nancy de los Ángeles, et al.
Publicado: (2022)

Characterization of an in vitro steatosis model simulating activated de novo lipogenesis in MAFLD patients
por: Kim, Woonghee, et al.
Publicado: (2023)

Uncovering Actions of Type 3 Deiodinase in the Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
por: Marschner, Rafael Aguiar, et al.
Publicado: (2023)

Metabolic dysfunction–associated fatty liver disease (MAFLD): an update of the recent advances in pharmacological treatment
por: Sangro, Paloma, et al.
Publicado: (2023)

Pre-Clinical Insights into the Iron and Breast Cancer Hypothesis
por: Thompson, Henry J., et al.
Publicado: (2021)

How staph thwarts attack
por: Maxmen, Amy
Publicado: (2009)

Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)—A Condition Associated with Heightened Sympathetic Activation
por: Carnagarin, Revathy, et al.
Publicado: (2021)

Associations between red blood cell count and metabolic dysfunction-associated fatty liver disease(MAFLD)
por: Dai, Xinyi, et al.
Publicado: (2022)

MAFLD Criteria Guide the Subtyping of Patients with Fatty Liver Disease
por: Huang, Jiaofeng, et al.
Publicado: (2021)

Quantitative Assessment of Mammary Gland Density in Rodents Using Digital Image Analysis
por: McGinley, John N, et al.
Publicado: (2011)

Effects of Dietary Nutrients on Fatty Liver Disease Associated With Metabolic Dysfunction (MAFLD): Based on the Intestinal-Hepatic Axis
por: Yao, Nan, et al.
Publicado: (2022)

Adipose tissue dysfunction and MAFLD in obesity on the scene of COVID-19
por: Cordeiro, Adryana, et al.
Publicado: (2022)

Complementarity between Microbiome and Immunity May Account for the Potentiating Effect of Quercetin on the Antitumor Action of Cyclophosphamide in a Triple-Negative Breast Cancer Model
por: Manni, Andrea, et al.
Publicado: (2023)

Premenopausal Obesity and Breast Cancer Growth Rates in a Rodent Model
por: Matthews, Shawna B., et al.
Publicado: (2016)

From NAFLD to MAFLD: a “redefining” moment for fatty liver disease
por: Zheng, Kenneth I., et al.
Publicado: (2020)

The bidirectional impacts of alcohol consumption and MAFLD for progressive fatty liver disease
por: Kulkarni, Anand V., et al.
Publicado: (2023)

Polysaccharides: The Potential Prebiotics for Metabolic Associated Fatty Liver Disease (MAFLD)
por: Guo, Qin, et al.
Publicado: (2023)

Lead exposure as a causative factor for metabolic associated fatty liver disease (MAFLD) and a lead exposure related nomogram for MAFLD prevalence
por: Yang, Chenyu, et al.
Publicado: (2022)

FTO Polymorphisms are Associated with Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Susceptibility in the Older Chinese Han Population
por: Gu, Zhan, et al.
Publicado: (2020)

Targeting programmed cell death in metabolic dysfunction-associated fatty liver disease (MAFLD): a promising new therapy
por: Zhao, Jianan, et al.
Publicado: (2021)

Identification of Hepatic Dendritic Cells in Liver Biopsies in Patients with Metabolic Dysfunction-Associated Fatty Liver Diseas (MAFLD) and Obesity
por: Barranco-Fragoso, Beatriz, et al.
Publicado: (2022)

Impaired Glucagon-Mediated Suppression of VLDL-Triglyceride Secretion in Individuals With Metabolic Dysfunction–Associated Fatty Liver Disease (MAFLD)
por: Heebøll, Sara, et al.
Publicado: (2022)

What the New Definition of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Left Behind: Genetically Acquired Fatty Liver Disease (GAFLD)
por: Bril, Fernando
Publicado: (2021)

A Method for Serial Tissue Processing and Parallel Analysis of Aberrant Crypt Morphology, Mucin Depletion, and Beta-Catenin Staining in an Experimental Model of Colon Carcinogenesis
por: McGinley, John N, et al.
Publicado: (2010)

Liver Steatosis: Better Predictor of CKD in MAFLD Than Liver Fibrosis as Determined by Transient Elastography With Controlled Attenuation Parameter
por: Marc, Luciana, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8bnc75k0l0s60t697vnaaa0fgs